PFE•benzinga•
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%
Summary
Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 trial.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga